BioPharma

The suggestion so often deployed over the past two decades, that not every new medicine can be funded, is clearly no longer the case. With $20 million available every week, literally, everything approved as safe and effective by the TGA can now be funded.

Dr Brendan Shaw says the experience of the pandemic means Australians are now acutely aware of the existence of a global queue for new technologies, including vaccines, and that they are not at the front of it.

According to Bloomberg, the number of COVID-19 vaccines administered globally is 8.22 billion across 184 countries. The latest daily rate of doses administered is 37 million. COVAX has so far shipped over 610 million doses of COVID-19 vaccines to 144 participants.

The share price of Australian biopharmaceutical company Neuren almost doubled yesterday in response to positive results from a late-stage trial of its investigative treatment for Rett syndrome.

There are few similarities between reimbursement decision-making in Australia and New Zealand but they share a disconnect between public presentation and day-to-day reality.

New GSK boss Patrick Desbiens told BioPharmaDispatch he looks forward to supporting and contributing to the industry's busy work program in Australia.

According to Bloomberg, the number of COVID-19 vaccines administered globally is 8.09 billion across 184 countries. The latest daily rate of doses administered is 37.1 million. COVAX has so far shipped over 589 million doses of COVID-19 vaccines to 144 participants.

Organon's Luke Cornish said it is more important than ever for companies to have a "seat at the policy table" and that these conversations need to be held in the appropriate place.

GBMA chair Jane Halton AO PSM said she is proud to lead a growing membership base with a board comprised of some of the most experienced health executives in the country.

New Zealand has agreed to procure 60,000 doses of Pfizer's COVID-19 oral antiviral candidate, PF-07321332, subject to approval by the country's regulator.

"While countries like Japan, Germany, Austria and Great Britain get around 60% of their new medicines reimbursed within three months of registration, Australia only manages to get 2% reimbursed within three months," says the new report commissioned by Johnson & Johnson.

Janssen's Biljana Naumovic and Susan Martin of Johnson & Johnson Medical spoke with BioPharmaDispatch about the new report prepared by Dr Brendan Shaw of Shawview Consulting.